BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38334009)

  • 1. Association between plasma CTRPs with cognitive impairment and neurodegeneration of Alzheimer's disease.
    Huang X; Zhao J; Wang Q; Yan T; Gou S; Zhu X; Yang L; Ye F; Zhang J; Wang Y; Yang S; Le W; Xiang Y
    CNS Neurosci Ther; 2024 Feb; 30(2):e14606. PubMed ID: 38334009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Plasma Apolipoprotein M With Alzheimer's Disease: A Cross-Sectional Pilot Study From China.
    Xin JY; Huang X; Sun Y; Jiang HS; Fan J; Yu NW; Guo FQ; Ye F; Xiao J; Le WD; Yang SJ; Xiang Y
    Front Aging Neurosci; 2022; 14():838223. PubMed ID: 35370599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Andreasson U; Zetterberg H; Blennow K;
    JAMA Neurol; 2017 May; 74(5):557-566. PubMed ID: 28346578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.
    Pillai JA; Bena J; Bekris L; Kodur N; Kasumov T; Leverenz JB; Kashyap SR;
    Alzheimers Res Ther; 2023 Mar; 15(1):54. PubMed ID: 36927447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
    Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
    Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood Neurofilament Levels Predict Cognitive Decline across the Alzheimer's Disease Continuum.
    Lehmann S; Schraen-Maschke S; Vidal JS; Blanc F; Paquet C; Allinquant B; Bombois S; Gabelle A; Delaby C; Hanon O;
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
    JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification.
    Barthélemy NR; Bateman RJ; Hirtz C; Marin P; Becher F; Sato C; Gabelle A; Lehmann S
    Alzheimers Res Ther; 2020 Mar; 12(1):26. PubMed ID: 32183883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment.
    Giacomucci G; Mazzeo S; Bagnoli S; Ingannato A; Leccese D; Berti V; Padiglioni S; Galdo G; Ferrari C; Sorbi S; Bessi V; Nacmias B
    J Neurol; 2022 Aug; 269(8):4270-4280. PubMed ID: 35288777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios.
    Janelidze S; Barthélemy NR; He Y; Bateman RJ; Hansson O
    JAMA Neurol; 2023 May; 80(5):516-522. PubMed ID: 36987840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation Between Brain Structure Atrophy and Plasma Amyloid-β and Phosphorylated Tau in Patients With Alzheimer's Disease and Amnestic Mild Cognitive Impairment Explored by Surface-Based Morphometry.
    Li K; Qu H; Ma M; Xia C; Cai M; Han F; Zhang Q; Gu X; Ma Q
    Front Aging Neurosci; 2022; 14():816043. PubMed ID: 35547625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative Plasma Tau-PT217 and Tau-PT181 Are Associated With Postoperative Delirium.
    Liang F; Baldyga K; Quan Q; Khatri A; Choi S; Wiener-Kronish J; Akeju O; Westover MB; Cody K; Shen Y; Marcantonio ER; Xie Z
    Ann Surg; 2023 Jun; 277(6):e1232-e1238. PubMed ID: 35794069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral Markers of Vascular Endothelial Dysfunction Show Independent but Additive Relationships with Brain-Based Biomarkers in Association with Functional Impairment in Alzheimer's Disease.
    Drake JD; Chambers AB; Ott BR; Daiello LA;
    J Alzheimers Dis; 2021; 80(4):1553-1565. PubMed ID: 33720880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease.
    Lewczuk P; Ermann N; Andreasson U; Schultheis C; Podhorna J; Spitzer P; Maler JM; Kornhuber J; Blennow K; Zetterberg H
    Alzheimers Res Ther; 2018 Jul; 10(1):71. PubMed ID: 30055655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Tau Proteins as Potential Biomarkers for the Assessment of Alzheimer's Disease Progression.
    Nam E; Lee YB; Moon C; Chang KA
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study.
    Dong Y; Hou T; Li Y; Liu R; Cong L; Liu K; Liu C; Han X; Ren Y; Tang S; Winblad B; Blennow K; Wang Y; Du Y; Qiu C
    J Alzheimers Dis; 2023; 96(2):845-858. PubMed ID: 37899059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum neurofilament light chain in behavioral variant frontotemporal dementia.
    Steinacker P; Anderl-Straub S; Diehl-Schmid J; Semler E; Uttner I; von Arnim CAF; Barthel H; Danek A; Fassbender K; Fliessbach K; Foerstl H; Grimmer T; Huppertz HJ; Jahn H; Kassubek J; Kornhuber J; Landwehrmeyer B; Lauer M; Maler JM; Mayer B; Oeckl P; Prudlo J; Schneider A; Volk AE; Wiltfang J; Schroeter ML; Ludolph AC; Otto M;
    Neurology; 2018 Oct; 91(15):e1390-e1401. PubMed ID: 30209235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.